What Is the Cell Cycle and How Cancer Hijacks It

What Is the Cell Cycle?

The cell cycle is the highly regulated sequence of events through which a cell grows, duplicates its genetic material, and divides into two daughter cells. Every cell division in the human body — from the repair of a skin wound to the continuous renewal of intestinal lining — depends on the faithful execution of this cycle. In an adult human, roughly 25 million cells divide every second.

The cell cycle is not simply an on/off switch. It is an elaborate, multi-stage process with built-in quality controls that verify the integrity of DNA before allowing the cycle to proceed. These quality control mechanisms, called checkpoints, are the cell's primary defense against errors that could lead to cancer. Understanding the cell cycle is therefore inseparable from understanding the biology of cancer.

The Phases of the Cell Cycle

The cell cycle is divided into two broad phases: interphase (the preparation and growth phase) and M phase (mitosis and cytokinesis, when the cell actually divides).

Interphase comprises three stages:

• G1 phase (Gap 1): The cell grows, synthesizes proteins, and prepares for DNA replication. The G1/S checkpoint (restriction point) assesses whether conditions are favorable for division — adequate nutrients, sufficient cell size, and intact DNA.
• S phase (Synthesis): DNA replication occurs. Each of the 46 chromosomes is duplicated, creating 92 chromosomes arranged as 46 pairs of sister chromatids. DNA damage is monitored throughout.
• G2 phase (Gap 2): The cell continues to grow and checks that DNA replication is complete and accurate. The G2/M checkpoint verifies DNA integrity before committing to mitosis.

Some cells exit the cycle into a quiescent state called G0 — neurons and muscle cells, for example, remain in G0 for years or permanently. Others, like stem cells and epithelial cells, cycle continuously.

Mitosis and Cell Division

Mitosis is the process by which one nucleus divides into two genetically identical nuclei. It proceeds through four stages: prophase (chromosomes condense; mitotic spindle forms), metaphase (chromosomes align at the cell's equator; the spindle checkpoint verifies all chromosomes are properly attached), anaphase (sister chromatids are pulled to opposite poles), and telophase (nuclear envelopes reform around each set of chromosomes).

Mitosis is followed by cytokinesis, the physical division of the cytoplasm, producing two daughter cells each containing a complete diploid genome. The entire process of division takes roughly 1 to 2 hours, while interphase typically spans 18 to 24 hours in rapidly dividing cells.

Checkpoint Mechanisms: The Cell's Quality Control

Three major checkpoints guard against errors during the cell cycle. Each is governed by a family of proteins called cyclin-dependent kinases (CDKs) and their regulatory partners, the cyclins. CDK activity rises and falls in waves through the cycle, phosphorylating key target proteins that advance the cycle or hold it in check.

• G1/S checkpoint: The most important checkpoint. The retinoblastoma protein (Rb) acts as a brake, preventing S phase entry. Growth factor signals and CDK4/6-cyclin D complexes phosphorylate and inactivate Rb, releasing the brake. Damage signals reinforce Rb's repressive role through the p53 pathway.
• G2/M checkpoint: Verifies that DNA replication is complete and undamaged before committing to mitosis. DNA damage activates kinases (ATM, ATR) that stabilize p53, which induces the CDK inhibitor p21, halting the cycle.
• Spindle assembly checkpoint (SAC): Delays anaphase until every chromosome is correctly attached to spindle fibers from both poles. Prevents chromosome missegregation — a primary cause of chromosomal instability in cancer.

How Cancer Hijacks the Cell Cycle

Cancer is fundamentally a disease of dysregulated cell division. Tumor cells accumulate mutations that dismantle checkpoint mechanisms, allowing unchecked proliferation. The most important targets are proto-oncogenes (accelerators of the cycle) and tumor suppressor genes (brakes on the cycle).

Proto-oncogenes encode growth factors, growth factor receptors, and signaling proteins that promote cell division. Gain-of-function mutations or amplifications convert them into oncogenes — permanently activated accelerators. The RAS gene, mutated in approximately 30 percent of all human cancers, encodes a signaling protein that becomes locked in its active, growth-promoting state.

Tumor suppressor genes encode proteins like Rb and p53 that restrain division. Loss-of-function mutations in both copies of a tumor suppressor (following the two-hit hypothesis of Alfred Knudson) remove the brakes. p53, often called the guardian of the genome, is mutated or inactivated in over half of all human cancers. It normally halts the cycle or triggers apoptosis (programmed cell death) in response to DNA damage; its loss allows damaged cells to continue dividing and accumulating further mutations.

DNA Damage Response and Apoptosis

When DNA damage is too severe to repair, normal cells activate apoptosis — a program of orderly self-destruction that eliminates the damaged cell before it can become cancerous. The mitochondrial pathway of apoptosis, regulated by the BCL-2 family of proteins, is frequently disrupted in cancer. Overexpression of anti-apoptotic proteins like BCL-2 (found in follicular lymphoma through chromosomal translocation) prevents apoptosis, allowing damaged cells to survive and accumulate further mutations.

Cancer cells typically require six or more distinct mutations to achieve full malignancy — dysregulating growth signals, evading growth suppressors, resisting apoptosis, achieving replicative immortality (usually by activating telomerase), inducing angiogenesis, and eventually enabling invasion and metastasis. This multi-step progression, documented by Hanahan and Weinberg in their influential hallmarks of cancer framework, explains why cancer incidence increases dramatically with age: the accumulation of sufficient mutations simply takes time.

Therapeutic Implications

Understanding the cell cycle has directly driven cancer therapy. CDK4/6 inhibitors (palbociclib, ribociclib) block the kinases that release the G1/S checkpoint brake, halting cancer cell proliferation — now standard care for hormone receptor-positive breast cancer. PARP inhibitors exploit DNA repair deficiencies in BRCA-mutated cancers. Immune checkpoint inhibitors, while targeting a different checkpoint (immune suppression rather than the cell cycle), exemplify the translational power of understanding the molecular brakes that cancer exploits.